4D Molecular Therapeutics, Inc. Common Stock

FDMTNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
10.99 USD
↗ 0.15 (1.38%)AT CLOSE (11:59 AM EDT)
10.92
↘ 0.07 (0.64%)
POST MARKET (AS OF 07:29 PM EDT)
Post Market
AS OF 07:29 PM EDT
10.92
↘ 0.07 (0.64%)
🔴Market: CLOSED

Shares of 4D Molecular Therapeutics, Inc. Common Stock (FDMT) are trading at $10.98. Our models show a "Neutral" technical signal alongside a "Sell" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place FDMT at a fair price relative to peers.

Technical & fundamental data as of Jul 17, 2026.

Open?$10.51
High?$11.28
Low?$10.29
Prev. Close?$10.84
Volume?598.9K
Avg. Volume?993.1K
VWAP?$11.02
Rel. Volume?0.60x
Bid / Ask
Bid?$9.47 × 100
Ask?$13.11 × 100
Spread?$3.64
Midpoint?$11.29
Valuation & Ratios
Market Cap?566.7M
Shares Out?52.3M
Float?44.5M
Float %?85.2%
P/E Ratio?N/A
P/B Ratio?1.25
EPS?-$3.08
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Clinical-Stage Platforms
Employees
196
Market Cap
566.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.4dmoleculartherapeutics.com
Listed
2020-12-11
Address
5858 HORTON STREET #455
EMERYVILLE, CA 94608
Phone: (510) 505-2680
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
79
Momentum?
45
Short Sent.?
16
Piotroski F-Score?1/9Weak
Altman Z-Score?3.29Safe
Confidence?54%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?29.88%Squeeze Risk
Short Interest?13.3M
Days to Cover?9.1
Free Float44.5M
Avg Daily Volume1.5M
Settlement Date2026-06-30
Financial Health
Current Ratio?9.34Strong
Quick Ratio?9.34Strong
Cash Ratio?1.67Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
92
1.25CHEAP▾
P/S?
Peers
100
S&P
19
6.42FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.8CHEAP▾
EV/Sales?
Peers
100
S&P
31
5.60FAIR▾
Returns & Efficiency
ROE?
S&P
5
-35.6%WEAK▾
ROA?
S&P
3
-31.4%WEAK▾
Cash Flow & Enterprise
FCF?$-129544000
Enterprise Value?$494.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist